- Home
- GRTS
GRTS
Gritstone bio Inc.
as 05-17-2024 4:00pm EST
$.
+$.
+.%
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 102.4M | IPO Year: | 2018 |
| Target Price: | $5.33 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.67 - $3.33 | Next Earning Date: | 05-09-2024 |
| Revenue: | $15,645,000 | Revenue Growth: | 2.95% |
| Revenue Growth (this year): | -12.86% | Revenue Growth (next year): | 239.07% |
Share on Social Networks:
Latest Gritstone bio Inc. News
GRTS Breaking Stock News: Dive into GRTS Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Gritstone bio First Quarter 2024 Earnings: Misses Expectations
GlobeNewswire
8 days ago
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
15 days ago
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
GlobeNewswire
18 days ago
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
GlobeNewswire
19 days ago
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
GlobeNewswire
a month ago
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
GlobeNewswire
a month ago
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire
a month ago